Experimental GVAX/prednisone resulted in more deaths for castration-resistant prostate cancer

April 2009
Hem/Onc Today;4/10/2009, Vol. 10 Issue 7, p15
The article reports on the termination of VITAL-2, an international, multicenter phase-3 trial comparing GVAX immunotherapy for prostate cancer plus docetaxel against docetaxel plus prednisone after an independent data safety monitoring committee reported an imbalance of deaths between the study arms.


Related Articles

  • Current clinical trials testing the combination of immunotherapy with radiotherapy. Kang, Josephine; Demaria, Sandra; Formenti, Silvia // Journal for ImmunoTherapy of Cancer;9/20/2016, Vol. 4, p1 

    Increasing evidence demonstrates that radiation acts as an immune stimulus, recruiting immune mediators that enable anti-tumor responses within and outside the radiation field. There has been a rapid expansion in the number of clinical trials harnessing radiation to enhance antitumor immunity....

  • Alopecia patients turning to compounding R.Ph.s for help. Gebhart, Fred // Drug Topics;2/5/2001, Vol. 145 Issue 3, p28 

    Reports on the clinical trials of the topical immunotherapeutics compounded by pharmacists to treat alopecia areata (AA) which causes hair loss. Protective shields used by pharmacists in compounding; Disadvantages of immunotherapeutics; Problem with AA.

  • Rituxan� Immunotherapy and Zevalin� Radioimmunotherapy in the Treatment of Non-Hodgkin's Lymphoma. Christine A. White // Current Pharmaceutical Biotechnology;Aug2003, Vol. 4 Issue 4, p221 

    Immunotherapy with the anti-CD20 monoclonal antibody rituximab has been shown in clinical trials to be effective in the treatment of both indolent and aggressive non-Hodgkin's lymphomas (NHL). Recent studies have demonstrated improved clinical benefit with extended dose and maintenance therapies...

  • Amgen: Phase 3 results for melanoma therapy successful.  // Hem/Onc Today;5/25/2013, Vol. 14 Issue 10, p18 

    The article reports on the success of the clinical trial conducted by researchers at Amgen on the efficacy and safety of talimogene laherparepvec, an investigational oncolytic immunotherapy, compared to subcutaneous granulocyte-macrophage colony-stimulating factor for advanced unresected melanoma.

  • Introducing the clinical trials monitor: a new section of the journal for immunotherapy of cancer. Emens, Leisha A.; Romero, Pedro // Journal for ImmunoTherapy of Cancer;10/20/2015, Vol. 3, p1 

    The article discusses the editorial policy of the periodical, which feature the inclusion of clinical trials monitor for immunotherapy of cancer.

  • Second MAB trial needs participants.  // Inside MS;Spring98, Vol. 16 Issue 1, p6 

    Announces the need for participants for a double-blind, placebo-controlled clinical trials on the use of a monoclonal antibody called Antegren (natalizumab) for the treatment of acute multiple sclerosis (MS), around the United States. Description of the Antegren; Participation criteria; Contact...

  • Clinical Trials Targeting Advanced Cancers by Active Immunization of T-cell Defined Tumor Antigens. Ikeda, Hideyuki // Current Pharmaceutical Design;May2003, Vol. 9 Issue 14, p1133 

    Identification of CD8+ and CD4+ T-cell defined tumor antigens has opened the way for possible cancer immunotherapy. Peptide-based active immunization has begun mainly targeting melanoma. Surprisingly, some objective responses were obtained in the initial trials, leading to the accumulation of an...

  • CLINIC ROUNDUP.  // BioWorld Today;4/20/2010, Vol. 21 Issue 75, p8 

    This section offers news briefs on clinical trials including the positive results obtained by Jennerex Inc. from a Phase II trial using JX-594 for the treatment of advanced liver cancer and the first results reported by Stallergenes SA of a Phase II trial of its sublingual grass pollen...

  • Immunotherapy reassessed. Williams, C.J. // British Medical Journal (Clinical Research Edition);3/27/1982, Vol. 284 Issue 6320, p921 

    Examines the efficacy of immunotherapy of cancer. Vagueness in the mechanism of host resistance; Insufficiency of understanding of the mechanisms of various types of immunotherapy; Discrepancy in the result of several clinical trials on immunotherapy.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics